Tests letrozole added to maintenance treatment in estrogen receptor positive ovarian cancer
Tests letrozole or placebo alongside standard maintenance in adults with ovarian cancer.
Plain-language title generated from the registry record
Registry title: MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Key facts
- Where
- Berlin, Cologne, Deggendorf, Dresden, Duesseldorf, Essen, Esslingen am Neckar, Freiburg im Breisgau, Hamburg, Hildesheim, Konstanz, Mainz, Mannheim, Muenster, Munich, Ravensburg, Rosenheim, Schweinfurt, Ulm, Wiesbaden, Wolfsburg, and Wuppertal, GermanySee the 23 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women newly diagnosed with oestrogen-receptor positive ovarian, fallopian tube or peritoneal cancer. They must have had surgery and chemotherapy first. Some take letrozole, others take placebo.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Newly diagnosed FIGO stage II to IV low or high grade serous or endometrioid epithelial ovarian, fallopian tube or peritoneal cancer; at least 1% positive for ER expression; ECOG performance status 0-2
- Earlier treatment
- Debulking surgery (also after chemotherapy) and at least 4 cycles of platinum-based chemotherapy (before surgery is allowed)
- Biomarker or test result
- Oestrogen receptor (ER) positive, at least 1%, tested by the MATAO trial's own pathology facility; tumour tissue or ascites cell block must be available
Main reasons for not taking part
- Cancer got worse at the end of the earlier treatment
- Pregnant or breastfeeding women
- Women who can still have children, unless sterilised or getting surgery as stated in the record
- Another cancer in the last 5 years that affects the outlook
- Cannot take endocrine therapy, cannot swallow tablets, or has galactose or lactase intolerance
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Have you ever been told you have ovarian, fallopian tube or peritoneal cancer?
- What type of ovarian cancer do you have?
Source: NCT04111978, who can take part
Where in Germany
- Charite Universitaetsmedizin Berlin KöRBerlin, GermanyTaking people
- St. Elisabeth Krankenhaus GmbHCologne, GermanyTaking people
- DONAUISAR Klinikum Deggendorf-Dingolfing-Landau gKUDeggendorf, GermanyTaking people
- Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöRDresden, GermanyTaking people
- Universitaetsklinikum Duesseldorf AöRDuesseldorf, GermanyTaking people
- KEM I Evang. Kliniken Essen-Mitte gGmbHEssen, GermanyTaking people
- Klinikum Esslingen GmbHEsslingen am Neckar, GermanyTaking people
- Medical Center- University of FreiburgFreiburg im Breisgau, GermanyTaking people
- Agaplesion Diakonieklinikum Hamburg gGmbHHamburg, GermanyTaking people
- University Medical Center Hamburg-EppendorfHamburg, GermanyTaking people
- Frauenaerzte Am BahnhofsplatzHildesheim, GermanyTaking people
- Klinikum Konstanz GmbHKonstanz, GermanyTaking people
- Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöRMainz, GermanyTaking people
- Universitaetsklinikum Mannheim GmbHMannheim, GermanyTaking people
- Universitaetsklinikum Muenster AöRMuenster, GermanyTaking people
- Klinikum der Universitaet Muenchen AöRMunich, GermanyTaking people
- MVZ fuer Haematologie und Onkologie Ravensburg GmbHRavensburg, GermanyTaking people
- RoMed Klinikum RosenheimRosenheim, GermanyTaking people
- Leopoldina Krankenhaus der Stadt Schweinfurt GmbHSchweinfurt, GermanyTaking people
- Universitaetsklinikum Ulm AoRUlm, GermanyTaking people
- Helios Dr. Horst Schmidt Kliniken Wiesbaden GmbHWiesbaden, GermanyTaking people
- Klinikum WolfsburgWolfsburg, GermanyTaking people
- Helios Universitaetsklinikum WuppertalWuppertal, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Swiss GO Trial Group
- Trial code
- NCT04111978EU 2024-511219-78-00
- Record updated
- 29 September 2025
- Original description
The purpose of this study is to evaluate the efficacy of addition of letrozole to the standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor (ER) positive high and low grade epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) and subsequent primary treatment surgery and chemotherapy. Half of the participants will receive to the standard maintenance treatment, letrozole, whilst the other half receives placebo.Read full original descriptionShow less
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO), Including LOGOS (Low Grade Ovarian Cancer Sub-study).
The purpose of this study is to evaluate the efficacy of addition of letrozole to the standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor (ER) positive high and low grade epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) and subsequent primary treatment surgery and chemotherapy. Half of the participants will receive to the standard maintenance treatment, letrozole, whilst the other half receives placebo.
The study's primary hypothesis is that the treatment with letrozole increases progression free survival in comparison to the maintenance standard treatment (superiority trial).
Inclusion: Patients must be ≥ 18 years of age; Willing and able to attend the visits and to understand all study-related procedures; Primary, newly diagnosed FIGO Stage II to IV and histologically confirmed low or high grade serous or endometrioid epithelial ovarian/fallopian tube/peritoneal cancer; (Interval-) debulking performed ECOG-Performance Status 0-2; Signed informed consents (ICF-1; ICF-2); Paraffin-embedded tissue or paraffin-embedded cell block (from ascites) available; Positivity (≥ 1%) for ER expression (only determined by Histopathology Core Facility of MATAO trial); At least 4 cycles of platinum-based chemotherapy (neoadjuvant allowed); Negative serum pregnancy test in women of childbearing potential who will get/have gotten a surgical resection or radiation sterilization, prior to the intervention in the therapeutical maintenance setting.
Exclusion: Women of childbearing potential (not having undergone a surgical or radiation sterilization and not getting a surgical resection, prior to the intervention in the therapeutical maintenance setting); < 4 cycles of chemotherapy in total; Contraindications to endocrine therapy; Progressive disease at the end of adjuvant treatment as defined in chapter 9.2.1 of protocol; Any other malignancy within the last 5 years which has impact on the prognosis of the patient; Patients with a known intolerance to galactose, lactase deficiency and glucose-galactose malabsorption; Pregnant or lactating women; Inability or unwillingness to swallow tablets.